| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2008-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2009-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2123285-A1 |
| titleOfInvention |
Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy |
| abstract |
The present invention relates to nucleosidic phosphoantigens for the treatment of the human or animal body by therapy. The invention also relates to a method for stimulating Vγ9Vδ2 T cell-mediated immune response, which comprises the step of administering to a subject in need thereof a therapeutically effective amount of nucleosidic phosphoantigens. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8323664-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010086617-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2467436-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8198430-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8609108-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8790910-B2 |
| priorityDate |
2008-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |